EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies

Eric L Simpson, Emma Guttman-Yassky, Jeffrey Pawlikowski, Eric G Ghorayeb, Takayuki Ota, Mark G Lebwohl

Archives of Dermatological Research · 2024

DOI: 10.1007/s00403-024-03319-z ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Archives of Dermatological Research, 2024. Verfasst von Eric L Simpson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, South Waterfront, 3303 S. Bond Ave, Portland, OR, 97239, USA. simpsone@ohsu.edu. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Interleukin-1alpha. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceutical Companies of Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bermekimab is a human-derived recombinant monoclonal antibody that exhibits immunoregulatory activity by specifically blocking interleukin-1α activity. Four phase 2 studies evaluated efficacy and safety of bermekimab in patients with moderate-to-severe atopic dermatitis (AD). In addition, a novel human skin explant model was developed to assess bermekimab pharmacokinetics/pharmacodynamics and proteomic/transcriptomic effects. Study 1 (NCT03496974, N = 38) was an open-label, dose escalation study of subcutaneous bermekimab (200 mg or 400 mg). Study 2 (NCT04021862, N = 87) was a double-blind, placebo-controlled, randomized (1:1:1) study of subcutaneous bermekimab (400 mg every week (qw) or every 2 weeks) or placebo. GENESIS (NCT04791319, N = 198) was a double-blind, placebo- and active-comparator-controlled, randomized (1:1:2:2) study of placebo, subcutaneous bermekimab (350 mg or 700 mg qw), or dupilumab. LUNA (NCT04990440, N = 6) was a double-blind, placebo-controlled, randomized (4:1) study of intravenous bermekimab 800 mg qw or placebo. A novel human ex vivo skin pharmacodynamic assay supported phase 0 (NCT03953196) and phase 1 (NCT04544813) studies. In Study 1, 400 mg subcutaneous bermekimab showed improvement in efficacy assessments (e.g., ≥ 75% improvement of EASI over baseline, IGA 0/1, and worst itch); however, efficacy was not confirmed in Study 2 or GENESIS. Consequently, GENESIS and LUNA were terminated early. The novel human ex vivo skin pharmacodynamic assay demonstrated that bermekimab reduced downstream skin injury responses. Although bermekimab showed potential as an AD treatment in preclinical and early open-label trials, larger controlled studies (Study 2 and GENESIS) did not confirm those initial results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicInterleukin-1alphaAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDouble-Blind MethodInjections, SubcutaneousSeverity of Illness IndexSkinTreatment Outcome

Stichwörter der Autor:innen

Atopic dermatitisBermekimabInterleukin-1αMABp1Phase 2Subcutaneous

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedIL1A protein, humanInterleukin-1alpha

Autor:innen und Institutionen

  • Oregon Health & Science University, South Waterfront, 3303 S. Bond Ave, Portland, OR, 97239, USA. simpsone@ohsu.edu.
  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA.
  • Janssen Scientific Affairs, LLC, Horsham, PA, 19044, USA.
  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 19044, USA.
  • Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Förderung

  • Janssen Pharmaceutical Companies of Johnson & Johnson

Zitieren

APA

Simpson, E. L., Guttman-Yassky, E., Pawlikowski, J., Ghorayeb, E. G., Ota, T., & Lebwohl, M. G. (2024). Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies. Archives of Dermatological Research. https://doi.org/10.1007/s00403-024-03319-z

Vancouver

Simpson EL, Guttman-Yassky E, Pawlikowski J, Ghorayeb EG, Ota T, Lebwohl MG. Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies. Archives of Dermatological Research. 2024. doi:10.1007/s00403-024-03319-z

BibTeX
@article{Simpson2024,
  author = {Simpson, Eric L and Guttman-Yassky, Emma and Pawlikowski, Jeffrey and Ghorayeb, Eric G and Ota, Takayuki and Lebwohl, Mark G},
  title = {Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies},
  journal = {Archives of Dermatological Research},
  year = {2024},
  doi = {10.1007/s00403-024-03319-z}
}
Kostenlos starten →